Breast NeoplasmsNCT05812040

Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple Discharge

A study testing Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD) in people with Breast Neoplasms and Nipple Discharge, run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University at 1 site in China.

Completed

Finished. The study has ended and is not enrolling. Results may be posted on the official record.

Official record

Search all trials

Trial summary

Who is it for?: Ages 18 to 75 years, women only
Conditions the study is for: Breast Neoplasms, Nipple Discharge
What is being tested?: Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)
Could I receive a placebo?: No, everyone receives an active treatment
How many people: 134 participants
Where: 1 siteChina
Study dates: 21 Mar 2023to 30 Dec 2025
Phase: Interventional
Are there results?: None posted in the registry

Key requirements

Who can take part, as listed by the sponsor. Only the study team can confirm whether you are eligible, so take this list to your doctor.

Ages 18 to 75 years
Women only
No healthy volunteers
Adult, Older adult

Who may be able to join

Female patients aged between 18 and 75 years old.
Pathological nipple discharge patients who received treatment at Sun Yat-sen Memorial Hospital. The diagnostic criteria for pathological nipple discharge include unilateral, single duct orifice, and spontaneous discharge of serous or bloody fluid. Patients who meet any of the above criteria are considered as pathological discharge.
Willing to sign an informed consent form for clinical research and undergo HR-MRD and MRD examination.

Who cannot join

Patients who have undergone surgery on the nipple-areolar complex of the PND breast side within the past year.
Patients who have claustrophobia or metal implants in their body, which are not suitable for MRI scans.
Patients who are pregnant or breastfeeding.

Trial locations and contacts

1 site in 1 country.

China1 site

Sun Yat-Sen Memorial Hospital, Sun Yat-Sen University
Guangzhou, Guangdong, 510120

Other trials in China

About this study

Official title: Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple Discharge: A Prospective, Exploratory Diagnostic Study

Nipple discharge is one of the common symptoms of breast disease patients. Nipple discharge can be divided into physiological and pathological nipple discharge (PND). Among patients with PND symptoms who undergo biopsy, 5%-21% of them are malignant, and the risk of malignancy increases with age. The primary diagnostic imaging methods for PND patients include mammography and breast ultrasound. Nearly half of PND patients who undergo traditional mammography and ultrasound examination have negative findings, but this does not rule out the presence of malignant lesions. Central duct excision is the gold standard for PND diagnosis, but invasive surgery without imaging guidance can lead to some complications. Magnetic Resonance Ductography (MRD), which uses water imaging technology to visualize the inside of the duct without contrast injection, can show imaging features of ductal lesions such as filling defects, irregularities of duct walls, and ductal obstruction. However, previous studies have shown that the signal-to-noise ratio of MRD images needs to be improved. Microscopy coil has the characteristics of small voxels and high spatial resolution, making it suitable for high signal-to-noise ratio imaging of small superficial structures. This provides a hardware foundation for improving the quality of MRD images. Therefore, in this study, the investigators aim to use the 3T MR instrument and microscopy coil to perform non-invasive high-resolution Magnetic Resonance Ductography (HR-MRD) on PND patients to evaluate the ability of HR-MRD to detect PND causes and the imaging features of duct-related lesions on HR-MRD, to assist in the accurate diagnosis and treatment of PND.

Conditions: Breast Neoplasms, Nipple Discharge
Being tested: Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)
Medical subject headings: Breast Neoplasms, Galactorrhea

What participants receive

What participants receive. In a randomised study each person is assigned to one group by chance.

Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)Diagnostic test
all participants will receive Magnetic Resonance Ductography (MRD) and High-Resolution Magnetic Resonance Ductography (HR-MRD) examination, using breast dedicated coil and microscopic coil, respectively

Study groups in NCT05812040
Study group	Role	What they receive
MRD + HR-MRD	Other	Not described Receives: Diagnostic Test: Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)

What is being measured

The primary outcome is the main question the study is designed to answer.

Analyze the sensitivity and specificity of HR-MRD in detecting lesions that require surgical excision in patients with PND
Measured: 15 months

Secondary outcomes (2)

Analyze the PPV and NPV of HR-MRD in detecting lesions that require surgical excision in patients with PND
Measured: 15 months
The difference of detection sensitivity between HR-MRD and MRD in identifying lesions requiring surgical excision
Measured: 15 months

Timeline

From the start of the study to its completion; the mark is today. Estimated dates are the sponsor’s plan.

21 Mar 202330 Dec 2025

First posted13 Apr 2023
Study start21 Mar 2023
Primary completion30 Dec 2025
Study completion30 Dec 2025

Resources

Official record on ClinicalTrials.govThe registry entry this page is built from, with its full change history.
Publications (14)Papers the sponsor has linked to this study.
Other trials for Breast NeoplasmsStudies of the same condition, open and under way.
More trials run by Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityThe sponsor's other registered studies.
What the trial phases meanHow a treatment moves from first tests in people to approval.

More details

For doctors and researchers: how the study is designed, who runs it, and its registry IDs.

Study design

Study type: Interventional
Phase: Phase N/A
Primary purpose: Diagnosis
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Enrolment: 134 participants (actual)

IDs, dates and publications

ClinicalTrials.gov ID: NCT05812040
Sponsor's protocol ID: SYSKY-2023-122-02
Status last verified: Sep 2026
First submitted: 20 Mar 2023
Last updated: 21 Sep 2026
Results posted: No
Data monitoring committee: No
FDA-regulated drug: No
FDA-regulated device: No
Individual data sharing: No

Publications

Seltzer MH, Perloff LJ, Kelley RI, Fitts WT Jr. The significance of age in patients with nipple discharge. Surg Gynecol Obstet. 1970 Sep;131(3):519-22. No abstract available.
PubMed 5454537
Orel SG, Dougherty CS, Reynolds C, Czerniecki BJ, Siegelman ES, Schnall MD. MR imaging in patients with nipple discharge: initial experience. Radiology. 2000 Jul;216(1):248-54. doi: 10.1148/radiology.216.1.r00jn28248.
PubMed 10887256
Kanemaki Y, Kurihara Y, Itoh D, Kamijo K, Nakajima Y, Fukuda M, Van Cauteren M. MR mammary ductography using a microscopy coil for assessment of intraductal lesions. AJR Am J Roentgenol. 2004 May;182(5):1340-2. doi: 10.2214/ajr.182.5.1821340. No abstract available.
PubMed 15100142
Bhattarai N, Kanemaki Y, Kurihara Y, Nakajima Y, Fukuda M, Maeda I. Intraductal papilloma: features on MR ductography using a microscopic coil. AJR Am J Roentgenol. 2006 Jan;186(1):44-7. doi: 10.2214/AJR.04.1600.
PubMed 16357375
Fu P, Kurihara Y, Kanemaki Y, Okamoto K, Nakajima Y, Fukuda M, Maeda I. High-resolution MRI in detecting subareolar breast abscess. AJR Am J Roentgenol. 2007 Jun;188(6):1568-72. doi: 10.2214/AJR.06.0099.
PubMed 17515378
Hirose M, Nobusawa H, Gokan T. MR ductography: comparison with conventional ductography as a diagnostic method in patients with nipple discharge. Radiographics. 2007 Oct;27 Suppl 1:S183-96. doi: 10.1148/rg.27si075501.
PubMed 18180226
Kanemaki Y, Kurihara Y, Okamoto K, Nakajima Y, Fukuda M, Maeda I, Akiyama F. Ductal carcinoma in situ: correlations between high-resolution magnetic resonance imaging and histopathology. Radiat Med. 2007 Jan;25(1):1-7. doi: 10.1007/s11604-006-0091-5. Epub 2007 Jan 25.
PubMed 17225046
Zhu J, Kurihara Y, Kanemaki Y, Ogata H, Fukuda M, Nakajima Y, Maeda I. Diagnostic accuracy of high-resolution MRI using a microscopy coil for patients with presumed DCIS following mammography screening. J Magn Reson Imaging. 2007 Jan;25(1):96-103. doi: 10.1002/jmri.20809.
PubMed 17154376
Bahl M, Baker JA, Greenup RA, Ghate SV. Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI? Ann Surg Oncol. 2015 Dec;22 Suppl 3:S435-41. doi: 10.1245/s10434-015-4792-9. Epub 2015 Aug 7.
PubMed 26249144
Mann RM, Balleyguier C, Baltzer PA, Bick U, Colin C, Cornford E, Evans A, Fallenberg E, Forrai G, Fuchsjager MH, Gilbert FJ, Helbich TH, Heywang-Kobrunner SH, Camps-Herrero J, Kuhl CK, Martincich L, Pediconi F, Panizza P, Pina LJ, Pijnappel RM, Pinker-Domenig K, Skaane P, Sardanelli F; European Society of Breast Imaging (EUSOBI), with language review by Europa Donna-The European Breast Cancer Coalition. Breast MRI: EUSOBI recommendations for women's information. Eur Radiol. 2015 Dec;25(12):3669-78. doi: 10.1007/s00330-015-3807-z. Epub 2015 May 23.
PubMed 26002130
Nicholson BT, Harvey JA, Patrie JT, Mugler JP 3rd. 3D-MR Ductography and Contrast-Enhanced MR Mammography in Patients with Suspicious Nipple Discharge; a Feasibility Study. Breast J. 2015 Jul-Aug;21(4):352-62. doi: 10.1111/tbj.12417. Epub 2015 Apr 16.
PubMed 25882883
Berger N, Luparia A, Di Leo G, Carbonaro LA, Trimboli RM, Ambrogi F, Sardanelli F. Diagnostic Performance of MRI Versus Galactography in Women With Pathologic Nipple Discharge: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2017 Aug;209(2):465-471. doi: 10.2214/AJR.16.16682. Epub 2017 May 24.
PubMed 28537847
Expert Panel on Breast Imaging:; Lee SJ, Trikha S, Moy L, Baron P, diFlorio RM, Green ED, Heller SL, Holbrook AI, Lewin AA, Lourenco AP, Niell BL, Slanetz PJ, Stuckey AR, Vincoff NS, Weinstein SP, Yepes MM, Newell MS. ACR Appropriateness Criteria(R) Evaluation of Nipple Discharge. J Am Coll Radiol. 2017 May;14(5S):S138-S153. doi: 10.1016/j.jacr.2017.01.030.
PubMed 28473070
Gupta D, Mendelson EB, Karst I. Nipple Discharge: Current Clinical and Imaging Evaluation. AJR Am J Roentgenol. 2021 Feb;216(2):330-339. doi: 10.2214/AJR.19.22025. Epub 2020 Dec 9.
PubMed 33295815

Want to know more?

The sponsor has not listed a contact. The official record may have more details.

Talk to your doctor first and take this page with you. Only the study team can confirm whether you can join.

Questions to ask the study team

What is the study trying to find out?
What would I need to do, and how often would I visit?
Could I receive a placebo instead of the treatment?
What are the possible risks and benefits for me?
Will it cost me anything? Are travel or time paid for?
Can I keep seeing my own doctor during the study?
What happens when the study ends?

See locations

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8

All Breast Neoplasms trials

Study at a glance

From the registry record, last updated by the sponsor on 21 Sep 2026. Recruitment status is as the sponsor reported it: confirm with the study team.

Official title: Clinical Value of Breast High-Resolution MR Ductography in Patients With Pathological Nipple Discharge: A Prospective, Exploratory Diagnostic Study
ClinicalTrials.gov ID: NCT05812040
Acronym / sponsor ID: SYSKY-2023-122-02
Conditions: Breast Neoplasms, Nipple Discharge
Study type: Interventional
Recruitment status: Completed
Enrolment: 134 participants (actual)
Lead sponsor: Sun Yat-Sen Memorial Hospital of Sun Yat-Sen UniversityUniversity, hospital or other
Study start: 21 Mar 2023 (actual)
Primary completion: 30 Dec 2025 (actual)
Study completion: 30 Dec 2025 (actual)
First posted: 13 Apr 2023 (actual)
Results: Not posted in the source record

Clinical summary

The research question as the sponsor registered it. This describes what the study plans to test, not what it found.

Study design

Primary purpose: Diagnosis
Allocation: Not applicable
Intervention model: Single group
Masking: None (open label)
Number of arms: 1

Arm	Type	Receives
MRD + HR-MRD	Other	Diagnostic Test: Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)

Who may qualify

Ages: 18 to 75 years
Sex: Female only
Healthy volunteers: Not accepted
Age groups: Adult, Older adult

Key inclusion criteria (3 listed)

Female patients aged between 18 and 75 years old.
Pathological nipple discharge patients who received treatment at Sun Yat-sen Memorial Hospital. The diagnostic criteria for pathological nipple discharge include unilateral, single duct orifice, and spontaneous discharge of serous or bloody fluid. Patients who meet any of the above criteria are considered as pathological discharge.
Willing to sign an informed consent form for clinical research and undergo HR-MRD and MRD examination.

Key exclusion criteria (3 listed)

Patients who have undergone surgery on the nipple-areolar complex of the PND breast side within the past year.
Patients who have claustrophobia or metal implants in their body, which are not suitable for MRI scans.
Patients who are pregnant or breastfeeding.

Eligibility is decided by the study team after screening; this overview does not establish that a patient qualifies. Full inclusion and exclusion criteria.

Interventions

Intervention	Type	Arms
Magnetic Resonance Ductography (MRD); and High-Resolution Magnetic Resonance Ductography (HR-MRD)all participants will receive Magnetic Resonance Ductography (MRD) and High-Resolution Magnetic Resonance Ductography (HR-MRD) examination, using breast dedicated coil and microscopic coil, respectively	Diagnostic test	MRD + HR-MRD

Primary outcome

Analyze the sensitivity and specificity of HR-MRD in detecting lesions that require surgical excision in patients with PND
Time frame: 15 months

2 secondary outcomes

Analyze the PPV and NPV of HR-MRD in detecting lesions that require surgical excision in patients with PND
Time frame: 15 months
The difference of detection sensitivity between HR-MRD and MRD in identifying lesions requiring surgical excision
Time frame: 15 months

Results and safety

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

Research links

Official record on ClinicalTrials.govLast updated by the sponsor 21 Sep 2026.
Background: PubMed 5454537Seltzer MH, Perloff LJ, Kelley RI, Fitts WT Jr. The significance of age in patients with nipple discharge. Surg Gynecol Obstet. 1970 Sep;131(3):519-22. No abstract available.
Background: PubMed 10887256Orel SG, Dougherty CS, Reynolds C, Czerniecki BJ, Siegelman ES, Schnall MD. MR imaging in patients with nipple discharge: initial experience. Radiology. 2000 Jul;216(1):248-54. doi: 10.1148/radiology.216.1.r00jn28248.
Background: PubMed 15100142Kanemaki Y, Kurihara Y, Itoh D, Kamijo K, Nakajima Y, Fukuda M, Van Cauteren M. MR mammary ductography using a microscopy coil for assessment of intraductal lesions. AJR Am J Roentgenol. 2004 May;182(5):1340-2. doi: 10.2214/ajr.182.5.1821340. No abstract available.
Background: PubMed 16357375Bhattarai N, Kanemaki Y, Kurihara Y, Nakajima Y, Fukuda M, Maeda I. Intraductal papilloma: features on MR ductography using a microscopic coil. AJR Am J Roentgenol. 2006 Jan;186(1):44-7. doi: 10.2214/AJR.04.1600.
Background: PubMed 17515378Fu P, Kurihara Y, Kanemaki Y, Okamoto K, Nakajima Y, Fukuda M, Maeda I. High-resolution MRI in detecting subareolar breast abscess. AJR Am J Roentgenol. 2007 Jun;188(6):1568-72. doi: 10.2214/AJR.06.0099.
Background: PubMed 18180226Hirose M, Nobusawa H, Gokan T. MR ductography: comparison with conventional ductography as a diagnostic method in patients with nipple discharge. Radiographics. 2007 Oct;27 Suppl 1:S183-96. doi: 10.1148/rg.27si075501.
Background: PubMed 17225046Kanemaki Y, Kurihara Y, Okamoto K, Nakajima Y, Fukuda M, Maeda I, Akiyama F. Ductal carcinoma in situ: correlations between high-resolution magnetic resonance imaging and histopathology. Radiat Med. 2007 Jan;25(1):1-7. doi: 10.1007/s11604-006-0091-5. Epub 2007 Jan 25.
Background: PubMed 17154376Zhu J, Kurihara Y, Kanemaki Y, Ogata H, Fukuda M, Nakajima Y, Maeda I. Diagnostic accuracy of high-resolution MRI using a microscopy coil for patients with presumed DCIS following mammography screening. J Magn Reson Imaging. 2007 Jan;25(1):96-103. doi: 10.1002/jmri.20809.
Background: PubMed 26249144Bahl M, Baker JA, Greenup RA, Ghate SV. Evaluation of Pathologic Nipple Discharge: What is the Added Diagnostic Value of MRI? Ann Surg Oncol. 2015 Dec;22 Suppl 3:S435-41. doi: 10.1245/s10434-015-4792-9. Epub 2015 Aug 7.
Background: PubMed 26002130Mann RM, Balleyguier C, Baltzer PA, Bick U, Colin C, Cornford E, Evans A, Fallenberg E, Forrai G, Fuchsjager MH, Gilbert FJ, Helbich TH, Heywang-Kobrunner SH, Camps-Herrero J, Kuhl CK, Martincich L, Pediconi F, Panizza P, Pina LJ, Pijnappel RM, Pinker-Domenig K, Skaane P, Sardanelli F; European Society of Breast Imaging (EUSOBI), with language review by Europa Donna-The European Breast Cancer Coalition. Breast MRI: EUSOBI recommendations for women's information. Eur Radiol. 2015 Dec;25(12):3669-78. doi: 10.1007/s00330-015-3807-z. Epub 2015 May 23.
Background: PubMed 25882883Nicholson BT, Harvey JA, Patrie JT, Mugler JP 3rd. 3D-MR Ductography and Contrast-Enhanced MR Mammography in Patients with Suspicious Nipple Discharge; a Feasibility Study. Breast J. 2015 Jul-Aug;21(4):352-62. doi: 10.1111/tbj.12417. Epub 2015 Apr 16.
Background: PubMed 28537847Berger N, Luparia A, Di Leo G, Carbonaro LA, Trimboli RM, Ambrogi F, Sardanelli F. Diagnostic Performance of MRI Versus Galactography in Women With Pathologic Nipple Discharge: A Systematic Review and Meta-Analysis. AJR Am J Roentgenol. 2017 Aug;209(2):465-471. doi: 10.2214/AJR.16.16682. Epub 2017 May 24.
Individual participant dataSharing planned: No

Related trials for Breast Neoplasms

Active, not recruiting
Streamlined Geriatric and Oncological Evaluation Based On IC Technology
Breast Cancer, Comorbidities and Coexisting Conditions
RecruitingPhase 2
Gene Signatures to Guide HR+MBC Therapy in a Diverse Cohort
Invasive Mammary Carcinoma, Metastatic Breast Cancer
Not yet recruitingObservational study
Comparison of Reliability, Time Cost, and Participant Comfort of Lymphedema Assessments in Upper Extremity
Lymphedema, Upper Extremity Lymphedema
RecruitingPhase 3
A Study of Camrelizumab Plus Chemotherapy in Combination With or Without Famitinib as Neoadjuvant Therapy in Participants With Triple Negative Breast Cancer (BCTOP-T-N01)
TNBC - Triple-Negative Breast Cancer
RecruitingPhase 3
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8

Referral and contact

AzTrials does not enrol participants or take referrals. Contact the study team or a site listed below; they decide who can take part. This study is not recruiting at the moment.

Yue Hu, MD. principal investigator

Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University

1 site in 1 country: see every site and its status.

Questions about this trial

What is this clinical trial studying?

The full registered description is in the About this study section and the official record.

Who may be eligible to take part?

The sponsor lists 3 inclusion and 3 exclusion criteria. Eligibility is decided by the study team after screening, so read the full criteria and contact a listed site.

Is this clinical trial currently recruiting?

The record says: finished, as of the sponsor's last update on 21 Sep 2026. Status can change between updates, so confirm with the study contact before making plans.

Where is the study taking place?

The record lists 1 site in China. Whether a site is taking part right now should be confirmed with that site. See every site.

What are the possible benefits and risks?

They depend on the study and the treatment, and no study can promise a benefit. The study team explains the known risks during informed consent, before anyone joins; the record itself does not list them.

Are results available for this study?

The study is completed, but results are not available in the source record. That does not mean the treatment did or did not work.

How can a doctor refer a patient or contact the research team?

The record lists no contact. The official record names the sponsor, who can be asked directly. AzTrials does not enrol participants or take referrals.

What does the primary outcome measure?

Analyze the sensitivity and specificity of HR-MRD in detecting lesions that require surgical excision in patients with PND (time frame: 15 months). It is what the study was designed to measure, not a finding.

Where can I read the original study information?

On the ClinicalTrials.gov record for NCT05812040, which also lists 14 linked publications.

Does a listing mean the treatment is approved or proven to work?

No. A listing means the study is registered. It does not show that the treatment is safe, works, or is approved by a regulator.

How often is this information updated?

AzTrials copies changed records from ClinicalTrials.gov every night and reloads the whole registry every week. The sponsor last updated this record on 21 Sep 2026.